Trodelvy 200 mg is a groundbreaking antibody-drug conjugate (ADC) developed by Gilead Sciences, containing the active substance Sacituzumab Govitecan, designed specifically for the treatment of certain types of metastatic breast cancer and urothelial carcinoma. Trodelvy represents a new frontier in oncology treatments, combining targeted antibody therapy with a potent chemotherapy agent, enabling precision attack on cancer cells while minimizing damage to healthy tissues.
Key Product Details:
- Active Ingredient: Sacituzumab Govitecan-hziy 200 mg
- Form: Powder for Concentrate Solution for Infusion
- Route of Administration: Intravenous (IV) infusion
- Manufacturer: Gilead Sciences
- Packaging: 1 vial – sterile, cytotoxic
Key Benefits of Trodelvy 200 mg:
- Precision Oncology: Combines targeted antibody therapy with potent chemotherapy to selectively attack cancer cells.
- Metastatic Breast Cancer: Proven efficacy in treating triple-negative breast cancer (TNBC) patients who have previously undergone at least two systemic therapies.
- Urothelial Carcinoma: Approved for locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy and immune checkpoint inhibitors.
- Improved Survival: Clinical trials demonstrate a significant increase in progression-free survival and overall survival rates compared to traditional chemotherapy.
- Reduced Damage to Healthy Cells: Antibody-directed delivery system minimizes systemic toxicity compared to conventional chemotherapy.
How Does Trodelvy Work?
Trodelvy is an antibody-drug conjugate (ADC) that targets the Trop-2 protein, a surface antigen that is highly expressed in many epithelial cancers.
- Targeting Cancer Cells: The antibody component specifically binds to Trop-2 on cancer cells.
- Delivery of Chemotherapy: Once bound, Trodelvy releases the chemotherapy agent SN-38 directly into the cancer cell.
- Cell Death: SN-38 interferes with DNA replication, leading to cancer cell apoptosis (cell death).
Indications:
- Triple-Negative Breast Cancer (TNBC): For patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies.
- Urothelial Carcinoma: For patients with locally advanced or metastatic urothelial carcinoma who have received a platinum-based chemotherapy and an immune checkpoint inhibitor (PD-1/PD-L1).
Dosage and Administration:
- Recommended Dose: 10 mg/kg once weekly on Days 1 and 8 of a 21-day cycle.
- Infusion Duration: Administered as an IV infusion over 1 to 3 hours.
- Premedication: Anti-emetics recommended to prevent nausea and vomiting.
Safety Information:
- Common Side Effects: Neutropenia, diarrhea, nausea, fatigue, alopecia, anemia.
- Severe Reactions: Neutropenic fever, hypersensitivity, severe diarrhea.
- Hematologic Monitoring: Regular blood tests required due to risk of severe neutropenia.
- Pregnancy Warning: Can cause fetal harm; effective contraception is required during treatment.
Why Choose Trodelvy 200 mg?
Trodelvy 200 mg is at the forefront of targeted cancer therapy, offering renewed hope for patients battling aggressive forms of breast and urothelial cancer. Its dual mechanism of action not only targets Trop-2-expressing tumor cells but also ensures precise delivery of chemotherapy, making it an optimal choice for advanced cancer patients seeking a more effective and better-tolerated treatment option.
Storage Conditions:
- Temperature: Store refrigerated at 2°C to 8°C (36°F to 46°F).
- Protection: Keep vial in the original carton to protect from light. Do not freeze.
Buy Trodelvy 200 mg Online:
Secure your supply of Trodelvy 200 mg (Sacituzumab Govitecan) from our trusted pharmacy network. We offer fast and reliable delivery globally, ensuring that patients can access this life-changing treatment promptly.
Değerlendirmeler
Henüz değerlendirme yapılmadı.